Astellas Strikes $98M Deal In Prograf Antitrust MDL
Astellas Pharma US LLC will pay $98 million to resolve some of the suits in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf,...To view the full article, register now.
Already a subscriber? Click here to view full article